Lumos Pharma, Inc., a clinical-stage biopharmaceutical, announced a collaboration with Laura Dichtel, MD of Massachusetts General Hospital to evaluate the orally administered growth hormone (GH) secretagogue, LUM-201, in nonalcoholic fatty liver disease (NAFLD). The investigational new drug (IND) application for this pilot trial has received a study may proceed letter by the FDA.
